Generic Labeling: FDA Ponders Global Process Uniformity
This article was originally published in The Pink Sheet Daily
Executive Summary
Generic firms argue their data is not sufficient to recommend safety labeling changes, but FDA’s Dal Pan asks if they recommend changes in other countries, shouldn’t they be able to do the same in the US?